The main conference program incorporated over 30 presentations from some of the leaders in the field. Three particular highlights of the program were:

• Bristol-Myers Squibb discussed solutions to overcome key immuno-oncology challenges, including utilizing novel endpoints, optimizing collaboration strategies and bringing in next generation drug labelling approaches
• Merck shared comprehensive insights into their pembrolizumab program, including discussions around PD-L1 expression and the mutational landscape as part of the next generation of biomarker strategies.
• The FDA gave an invaluable regulatory perspective, dissecting approvals in the immune checkpoint inhibitor space before going on to discuss regulatory considerations in development programs including trial design and endpoints, biomarker strategies and safety issues.